In our approach, the only program parameters that need to be adjusted between cell lines and conditions include the frequency of imaging , and the average nuclear size. Other parameters that can be adjusted within the program include the area threshold for initial detection of a division even, the rate of intensity change required for detecting the interphase-prophase transition, and thresholds for rates of change in area. However, we found that these parameters did not need to be altered for the AP24534 Src-bcr-Abl inhibitor time-series approach to be able to detect changes in mitotic duration in another cell line. Analysis time becomes limiting when high-throughput imaging experiments are performed. Feature extraction is the rate-limiting step in our analysis platform. Our time-series algorithm requires only 2 features, both of which are in the geometric feature extraction category of DCELLIQ, leading to a total of 11 features extracted per nucleus. In contrast, the SVM approach uses features from multiple classes, meaning that in many cases all 211 features need to be extracted. Segmentation, tracking and feature extraction of the 11 geometric features required an average of 1.2 hours per movie. Similar analysis with all 211 features for SVM processing required an average of 3.4 hours per movie. Therefore, the time-series approach is almost three times as fast as the SVM-based approach when including time needed for feature extraction. The principal limitation of our approach is the selection bias that is imposed by the need to accurately track nuclei over long periods of time. We observed that the TSA can detect the IPT and MAT very accurately in nuclei that are successfully tracked by the program. We found that nuclei that were not successfully tracked showed a slightly longer average mitotic duration as compared to successfully tracked nuclei. However, despite this bias, DCELLIQ can successfully identify small perturbations in mitotic and interphase duration, because both tracked and non-tracked cell populations respond similarly to drug treatment. Thus, although DCELLIQ under-measures average mitotic duration, it accurately measures treatment effect size.